Treating patients like individuals



Mould DR, Upton RN, Wojciechowski J, Phan BL, Tse S, Dubinsky MC: Dashboards for the therapeutic monoclonal antibodies. AAPS J. Forthcoming 2018.       


Eser A, Primas C, Reinisch S, Vogelsang H, Novacek G, Mould DR, Reinisch W. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. J Clin Pharmacol. 2018 Jan 30. doi: 10.1002/jcph.1069. [Epub ahead of print]


Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. J Crohns Colitis. 2018;12(6):662-669.


Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR. Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. AAPS J. 2017;19(4):1136-1147.


Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. AAPS J. 2017 ;19(1):215-222


Mould DR, D'Haens G, Upton RN. Clinical Decision Support Tools: The Evolution of a Revolution. Clin Pharmacol Ther. 2016 ;99(4):405-18


Mould DR, Dubinsky MC. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55 Suppl 3:S51-9